PharmaSGP Holding SE banner

PharmaSGP Holding SE
XETRA:PSG

Watchlist Manager
PharmaSGP Holding SE Logo
PharmaSGP Holding SE
XETRA:PSG
Watchlist
Price: 28.8 EUR -0.69% Market Closed
Market Cap: €345.6m

Multiples-Based Value

There is not enough data to reliably calculate the multiples-based value of PSG.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PSG Multiples-Based Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

PSG Competitors Multiples
PharmaSGP Holding SE Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DE
PharmaSGP Holding SE
XETRA:PSG
345.3m EUR 3.8 24.3 18.3 18.4
US
Eli Lilly and Co
NYSE:LLY
900.7B USD 13.8 43.6 29.4 31.4
US
Johnson & Johnson
NYSE:JNJ
581B USD 6.2 21.7 15.1 18.5
UK
AstraZeneca PLC
LSE:AZN
236B GBP 5.3 30.6 16.9 23.8
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4 19.2 11.4 12.8
US
Merck & Co Inc
NYSE:MRK
304.8B USD 4.7 16.7 10.3 12.6
CH
Novartis AG
SIX:NOVN
229.9B CHF 5.2 20.8 12.9 16.6
IE
Endo International PLC
LSE:0Y5F
244.4B USD 105.4 -83.6 386.8 970
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.5 10.5 7.8 9.1
US
Pfizer Inc
NYSE:PFE
156.2B USD 2.5 20.1 7.7 10.3
US
Bristol-Myers Squibb Co
NYSE:BMY
119.2B USD 2.5 16.9 7.1 8.8
P/E Multiple
Earnings Growth PEG
DE
PharmaSGP Holding SE
XETRA:PSG
Average P/E: 22.4
24.3
17%
1.4
US
Eli Lilly and Co
NYSE:LLY
43.6
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
21.7
7%
3.1
UK
AstraZeneca PLC
LSE:AZN
30.6
26%
1.2
CH
Roche Holding AG
SIX:ROG
19.2
14%
1.4
US
Merck & Co Inc
NYSE:MRK
16.7
14%
1.2
CH
Novartis AG
SIX:NOVN
20.8
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
1%
10.5
US
Pfizer Inc
NYSE:PFE
20.1
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.9
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DE
PharmaSGP Holding SE
XETRA:PSG
Average EV/EBITDA: 47.6
18.3
8%
2.3
US
Eli Lilly and Co
NYSE:LLY
29.4
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
15.1
2%
7.5
UK
AstraZeneca PLC
LSE:AZN
16.9
13%
1.3
CH
Roche Holding AG
SIX:ROG
11.4
6%
1.9
US
Merck & Co Inc
NYSE:MRK
10.3
3%
3.4
CH
Novartis AG
SIX:NOVN
12.9
5%
2.6
IE
E
Endo International PLC
LSE:0Y5F
386.8
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.8
1%
7.8
US
Pfizer Inc
NYSE:PFE
7.7
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DE
PharmaSGP Holding SE
XETRA:PSG
Average EV/EBIT: 102.9
18.4
19%
1
US
Eli Lilly and Co
NYSE:LLY
31.4
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.5
6%
3.1
UK
AstraZeneca PLC
LSE:AZN
23.8
21%
1.1
CH
Roche Holding AG
SIX:ROG
12.8
6%
2.1
US
Merck & Co Inc
NYSE:MRK
12.6
6%
2.1
CH
Novartis AG
SIX:NOVN
16.6
9%
1.8
IE
E
Endo International PLC
LSE:0Y5F
970
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.6
US
Pfizer Inc
NYSE:PFE
10.3
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett